Job Trends
Rampart Bioscience was working on a platform to deliver gene therapies without the need for viral vectors.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.
Job listings in the area have ticked up in the last month. These seven companies are hiring in South San Francisco right now, including scientist and clinical roles.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Career Advice
Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.
THE LATEST
The company will open a new $11.6 million plant in Green County.
The medical device manufacturer will soon call Berkeley County home.
Amneal is planning an expansion of its New York facilities that will create hundreds of jobs as it and Impax Labs near completion of a planned merger.
Most investors and analysts are expecting 2018 to be a big year for mergers and acquisitions.
Sanofi has announced major restructuring, which will involve layoffs.
The deal has Sanofi paying $105 per share in cash.
The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.
Life sciences professionals don’t have to look far for opportunity in Genetown.
The survey of 51 oncologists suggests broad uptake of Imfinzi in advanced lung cancer patients who can’t be treated with surgery.
Astra has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reuters reported Thursday.